Tilmanocept
Phase 1Withdrawn 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Arthritis, Rheumatoid
Conditions
Arthritis, Rheumatoid
Trial Timeline
Sep 1, 2017 → Mar 1, 2018
NCT ID
NCT03241446About Tilmanocept
Tilmanocept is a phase 1 stage product being developed by Navidea Biopharmaceuticals for Arthritis, Rheumatoid. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03241446. Target conditions include Arthritis, Rheumatoid.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03241446 | Phase 1 | Withdrawn |
| NCT02683421 | Phase 1 | Completed |
Competing Products
20 competing products in Arthritis, Rheumatoid
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tc99m tilmanocept | Navidea Biopharmaceuticals | Phase 2 | 44 |
| KPL-404 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| Baricitinib + Methotrexate + Baricitinib Placebo + MTX Placebo + Folic Acid | Eli Lilly | Phase 3 | 77 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| LY2828360 + Placebo | Eli Lilly | Phase 2 | 52 |
| Investigational Medical Product (IMP) administered in parent study | Eli Lilly | Phase 3 | 77 |
| Sonelokimab | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Sonelokimab + Placebo + Adalimumab | MoonLake Immunotherapeutics | Phase 2 | 47 |
| Sonelokimab + Placebo | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Sonelokimab + Placebo + Risankizumab | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Dose A VTX958 + Dose B VTX958 + Placebo | Ventyx Biosciences | Phase 2 | 47 |
| LY2127399 | Eli Lilly | Phase 3 | 77 |
| Ixekizumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine + Sugar pill | Eli Lilly | Approved | 85 |
| Ixekizumab + Tirzepatide | Eli Lilly | Pre-clinical | 23 |
| Ixekizumab + Tirzepatide | Eli Lilly | Phase 3 | 77 |
| Baricitinib + TNF Inhibitor | Eli Lilly | Approved | 85 |
| Ixekizumab + Adalimumab | Eli Lilly | Approved | 85 |
| UBX0101 or placebo | Unity Biotechnology | Pre-clinical | 15 |
| UBX0101 | Unity Biotechnology | Phase 1 | 25 |